Proehl Gerald T - Jan 3, 2022 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
President, CEO and Chairman, Director, 10%+ Owner
Signature
/s/ Gerald T. Proehl Attorney-in-Fact
Stock symbol
DRMA
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 05:58 PM
Previous filing
Nov 26, 2021
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRMA Stock Option (right to buy) Award $0 +198K $0.00 198K Jan 3, 2022 Common Stock 198K $1.88 Direct
transaction DRMA Stock Option (right to buy) Award $0 +4.52K $0.00 4.52K Jan 3, 2022 Common Stock 4.52K $2.07 Direct
transaction DRMA Stock Option (right to buy) Award $0 +42.1K $0.00 42.1K Jan 3, 2022 Common Stock 42.1K $2.07 Direct F1
transaction DRMA Stock Option (right to buy) Award $0 +57.9K $0.00 57.9K Jan 3, 2022 Common Stock 57.9K $1.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.